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A B S T R A C T
Focussed studies on imidazopyridine inhibitors of Plasmodium falciparum cyclic GMP-dependent protein kinase
(PfPKG) have significantly advanced the series towards desirable in vitro property space. LLE-based approaches
towards combining improvements in cell potency, key physicochemical parameters and structural novelty are
described, and a structure-based design hypothesis relating to substituent regiochemistry has directed efforts
towards key examples with well-balanced potency, ADME and kinase selectivity profiles.
Malaria is one of the most prevalent infectious diseases of the de-
veloping world in humans, whose causative agent is the protozoan
parasite Plasmodium, with most deaths caused by P. falciparum. Despite
being largely preventable and treatable, it was responsible for 435,000
deaths in 2017; young children and pregnant women in sub-Saharan
Africa are particularly at risk.1 In addition to continuing challenges in
the contexts of policy development and socio-economic impact,2 the
observation of increasing resistance to current standard-of-care treat-
ments is significant. This is driving research and development efforts to
uncover new mechanisms by which the disease can be controlled and
prevented.3
Studies on the malarial kinome continue to provide well char-
acterised and credible new targets for antimalarial small molecule drug
discovery.4,5 The cGMP-dependent kinase PfPKG is one kinase which
meets many of the criteria for such a target. Pharmacological char-
acterisation using early chemical inhibitors in combination with reverse
genetics has demonstrated the important role of this enzyme in nu-
merous critical processes in the malaria life cycle.6–11 Following pre-
vious experience with progressing chemical inhibitors of other im-
portant malarial kinases,12–15 we have recently begun to disclose our
efforts to develop a series of PfPKG inhibitors based upon both bi-
cyclic16 and monocyclic scaffolds.17 In the bicyclic series, a number of
advanced analogues were shown to possess promising in vitro activity, a
well-defined mechanism of action and property profiles which trans-
lated to target-driven efficacy in vivo.16 An ongoing objective is to de-
velop this chemical series with a view to improving key physiochemical
parameters and compound novelty whilst retaining cell potency and
lipophilic ligand efficiency (LLE).19
A recent report from us described initial efforts towards these goals
by evaluating the aminopyrimidine hinge binding motif, bicyclic core
structure and basic substituent positioning.20 Investigation of each of
those structural features was found to be both necessary and produc-
tive, and the resulting compound profiles pointed strongly to retaining
these motifs in their original forms. As a result, the profiles of analogues
such as 1 (Figure 1) challenged us to consider additional strategies for
re-positioning the series in suitable ADME property space whilst
maintaining suitable levels of in vitro activity and improving compound
novelty. A first approach was to reduce the size of the 4-fluorophenyl
motif to lower lipophilicity and hence increase lipophilic ligand effi-
ciency (LLE)19 (Figure 1 – A). Previous SAR20 suggested potency could
be regained by enlarging the pyrimidine substituent, if needed (Figure 1
– B). In a second set of analogues, it was anticipated that re-design of
the benzylic dimethylaminomethyl side chain in the prototypical in-
hibitor compound 2 would enable lowering of logD (for example by
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increasing chain length and basicity) and could also address one likely
point of metabolic liability (for example by replacing the benzylic
carbon atom with a heteroatom) (Figure 1 – C). Here we discuss the
results of these investigations and show their significant beneficial
impact against the above criteria.
We first examined the possibility of improving the lipophilic effi-
ciency by focusing on the large 4-fluorophenyl motif, and initially re-
tained the original basic substituent at the 7-position of the bicyclic
core in doing so. The main design emphasis was to attempt to balance
the size of the pyrimidine substituent with a smaller lipophilically ef-
ficient replacement for the 4-fluorophenyl group. Among a small set of
initial replacements, prepared by the general route shown in Scheme 1,
the cyclopropyl analogue 9 was of lower potency in a biochemical
assay21 as compared to 2, but significantly also showed a lower mLogD
value of 1.7 of 1.7 (Table 1).22 Given that potency was lower than
desirable, further analogues incorporating the cyclopropyl group were
designed to combine a lower mlogD with improvements in potency and
LLE. Hence a set of compounds with larger groups appended to the
aminopyrimidine nitrogen was prepared using variations of the same
chemical approach. Small alkyl groups such as that in 10 did not pro-
vide any further boost in activity or LLE but, in line with previous SAR,
arylaminopyrimidines such as 11 and 12 were more biochemically
active and possessed the anticipated trend towards lower mLogD. The
most balanced profile was achieved in 13,23 which showed similar le-
vels of both biochemical potency and anti-malarial activity in a blood
stage hypoxanthine incorporation (HXI) cell assay21 compared to 2,
Figure 1. In vitro profiles of imidazopyridine 1 and 2,
and design modifications to be applied to 2: A –
truncate the aryl group; B – enlarge the pyrimidine
substituent if required; C – re-design the basic sub-
stituent. ADME data: mLogD=measured logD;
MLM=% remaining after 30min incubation with
mouse liver microsomes.
Scheme 1. Reagents and conditions: (i) LiHMDS, R1CO2Et, THF, −78 °C – rt, 3 h, 27–76%; (ii) Bu4NBr3 or NBS, CH2Cl2, rt, 2 h; (iii) 2-aminopyridine-4-methanol,
EtOH, 4 Å sieves, 100 °C, 18 h, 12–44% for two steps; (iv) MsCl, Et3N, THF, 0 °C, 1 h or SOCl2, CH2Cl2, 50 °C, 1 h; (v) Me2NH, THF, 0 °C – rt, 33–65% for two steps; (vi)
H2O2, Na2WO4·2H2O, AcOH, MeOH, 0 °C – rt, 3 h; (vii) for 7–9: NH4OAc, melt, 130 °C, 3 h, 5–27% for two steps; for 10: iPrNH2 (neat), 60 °C 3 h, 23% for two steps;
for 11: 2-aminopyridine (excess), NMP, microwave, 150 °C, 3 h, 8% for two steps; for 12: 4-(4-methylpiperazino)aniline, neat, microwave, 170 °C, 15min, 5% for two
steps; for 13: 4-(4-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester, TFA, sBuOH, 110 °C, 6 h, then TFA, CH2Cl2, rt, 2 h, 10% for three steps.
Table 1
Replacing the 4-fluorophenyl group with a cyclopropyl motif.
Compound R1 PfPKG
pIC50
Pf HXI
pEC50a
LLE mLogD
2 – 8.70 6.44 6.3 2.4
9 H 7.45 nt 5.8 1.7
10 7.36 nt 4.4 3.0
11 8.06 5.76 5.8 2.5
12 8.14 6.95 6.0 2.1
13 8.35 6.70 6.8 1.5
a nt=not tested.
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coupled with improvements in mLogD and LLE.
Turning next to the basic substituent on the bicyclic core, a small
number of molecules were initially designed to identify the optimum
position at which to locate this motif. We decided to employ the
benzylic dimethylaminomethyl group present in 2 for this analysis.
Docking of 2 and its 5-, 6- and 8- regioisomers into an apo-structure of
PfPKG (PDB:5DYK24) suggested that the best site for that substituent
was at the 7-position (Figure 2). The location of the positively charged
basic center between two acidic protein residues (E625 and D682) was
judged to be optimal for that particular group. Whilst relocating to the
6- or 8- positions appeared to be spatially tolerable, sub-optimal in-
teraction with the acids and a subsequent loss in affinity was predicted.
Appending several possible groups at the 5-position appeared to result
in a significant steric clash with the pyrimidine hinge binding motif
(data not shown); this was predicted to cause a significant loss of ac-
tivity and hence was not pursued.
This hypothesis was tested by synthesizing the 8- and 6-regioi-
somers 15 and 16 respectively. Using variations of previously described
chemical approaches,18,20 compounds 15 and 16 could be prepared
from the bromoketone building block 1425 (Scheme 2), in good yields
over 5 synthetic steps.
These two compounds showed reductions in their biochemical ac-
tivity, as compared to 2 (Table 2), which were in line with predictions
from the docking studies. Lipophilic ligand efficiency for the 8-sub-
stituted compound 15 was also higher than for 6-analogue 16, in part
due to an interesting divergence in mLogD (values of 1.6 for 15, 2.3 for
16, as compared to 2.4 for 2). However, the key factor of lower syn-
thetic accessibility for 8-position analogues emerged, which directed
our efforts away from preparing further compounds of this kind. In
contrast, the position of the two key acidic residues at the binding
pocket mouth implied that re-design of the basic substituent into longer
chain variants and appropriate conformationally constrained versions
might be productive. This design hypothesis suggested that substituents
of these new types at either the 6- or 7-positions should be evaluated.
We tested this proposal by making compounds bearing such mod-
ifications to the dimethylaminomethyl side chain in 2, and chose to
include adjustments in both expected pKa and conformation by varying
Figure 2. Docking of 2 (left), the 8-regioisomer 15 (centre) and the 6-regioisomer 16 (right) into an apo-PfPKG crystal structure (PDB:5DYK24), with protein surface
coloured by electrostatic potential. H-bonds and charge interactions are shown as dashed lines.
Scheme 2. Reagents and conditions: (i) 2-aminopyridine-3-methanol (for 15) or 2-aminopyridine-5-methanol (for 16), MeCN, NaHCO3, 90 °C, 18 h: 32–75%; (ii) MsCl,
Et3N, THF, 0 °C, 4 h; (iii) Me2NH, THF, 0 °C – rt, 3 h, 60–89% for two steps; (iv) H2O2, Na2WO4·2H2O, AcOH, MeOH, rt, 3 h; (v) NH4OAc, melt, 120 °C, 3 h, 19–27%
for two steps.
Table 2
Position of basic substituent attachment.
Compound Substituent position PfPKG pIC50 LLE
2 7 8.70 6.3
15 8 7.53 5.9
16 6 7.29 5.0
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the linking atom, chain length and ring size in new analogues.
Preparation of key intermediates 17–19 in three steps, followed by
palladium-catalysed aminations or microwave-mediated direct dis-
placements provided the N-linked and O-linked examples 20–27 re-
spectively (Scheme 3).26 The 7-C-linked analogue 29 was also prepared
in four synthetic steps from intermediate 28, which was itself con-
structed by condensing bromoketone 14 with the appropriate building
block 2-(2-aminopyridin-4-yl)ethan-1-ol.
These analogues (along with the earlier example 16) demonstrated
that extending via a conformationally constrained basic group (as in 20)
or via an open chain version (as in 21) at either the 7- or 6-position of
the core could each provide good biochemical potency (Table 3). Nei-
ther of these compounds appeared to possess a particular advantage in
any aspect of their in vitro profiles as compared to 2. Interestingly, the
related pair of piperazine regioisomers 22 and 23 showed a subtle
contrast in mLogD, where the 6-isomer 23 was found to possess the
lower value. The cell activity of 23 was also slightly lower as compared
to 22. Synthetic access to 6-substituted compounds was also found to be
generally less efficient; considering this and other contributing fac-
tors,27 we decided to focus additional efforts on 7-linked analogues
only.
Using the same synthetic chemistry as shown in Scheme 3, a small
additional set of 7-substituted analogues was prepared and evaluated
(Table 4). As compared to 20, increasing the ring size and hence al-
tering the conformational constraint in 24 gave modest improvements
in biochemical potency and cell activity, though only a slight change to
LLE. Microsomal stability was improved significantly, perhaps due to
constraining the conformation in the basic side chain. For the open
chain examples 25 and 29, in vitro ADME profiles very similar to 2
could be obtained, though both showed lower biochemical activity (and
hence no further benefit in LLE) and microsomal stability had not im-
proved. Both LLE and microsomal stability could be improved by re-
turning to a nitrogen-linked design in the open chain analogue 26, for
which the essentially unchanged mLogD (as compared to 25 and 29)
was accompanied by better biochemical potency and LLE. Finally, po-
sitioning an additional carbon atom within the aminopyrimidine group
gave 27; this notable compound showed an excellent balance of good
biochemical potency, in vitro activity against the parasite and improved
LLE and mLogD values. The effect of the secondary aminopyrimidine
(in 27) on microsomal stability, relative to the primary aminopyr-
imidine (in 26), was also significant.
The two most promising compounds identified − 13 and 27 – were
profiled and compared in vitro (Table 5). In addition to previously de-
scribed improvements in mLogD and LLE, high kinetic solubility
(measured using PBS at pH7.4 as buffer) was maintained in each case
and both compounds were shown to be non-cytotoxic. Despite a
Scheme 3. Reagents and conditions: (i) 2-amino-4-bromopyridine or 2-amino-5-bromopyridine, EtOH, 4 Å sieves, 80 °C, 18 h, 20–36%; (ii) H2O2, Na2WO4·2H2O,
AcOH, MeOH, rt – 50 °C, 18 h; (iii) For R1=H: NH4OAc, melt, 130 °C, 18 h, 30–52% for two steps; for R1=Me: Me2NH, THF, 70 °C, 18 h, 56% for two steps; (iv) for
R2= amine: Pd(OAc)2, JohnPhos, R2NH, NaOtBu, dioxane, 100 °C, 18 h, 3–29%; (v) for R2= alcohol: KOtBu, ROH, NMP, microwave, 170 °C, 10min, 6%; (vii) MsCl,
Et3N, THF, 0 °C, 1 h; (vi) Me2NH, THF, 60 °C, 10 h, 49% for two steps.
Table 3
Basic side chain variations.
Compound R1 PfPKG pIC50 Pf HXI pEC50a LLE mLogD
2 7-CH2NMe2 8.70 6.44 6.3 2.4
16 6-CH2NMe2 7.29 nt 5.0 2.3
20
7-
8.07 6.07 6.0 2.1
21 6-NH(CH2)3NMe2 7.90 nt 5.7 2.2
22 7- 8.48 6.58 5.4 3.1
23 6- 8.58 6.06 5.8 2.8
a nt=not tested.
J.M. Large, et al. Bioorganic & Medicinal Chemistry Letters 29 (2019) 126610
4
significantly lower mLogD value, the mouse microsomal stability of 13
surprisingly remained at the same level as for 2, for which we have no
clear explanation.28 In particular, 27 matched excellent biochemical
and cell potency with significantly higher stability in mouse micro-
somes to give a highly promising and well-balanced overall profile.
Selectivity was assessed by screening 13 and 27 against a human kinase
panel29 at a single 1 µM concentration (Figure 3). As expected, the
smaller cyclopropyl motif in 13 resulted in a decreased level of se-
lectivity, whilst 27 showed an excellent selectivity profile against the
kinases screened. We also tested compounds 2 and 27 against the two
human orthologues of PKG; no activity was observed up to a top assay
concentration of 1 µM,30 indicating a high level of selectivity for the
malarial kinase.
We have reported here the results of our continuing effort to pro-
gress a series of imidazopyridines as inhibitors of PfPKG, focusing on
alteration of the 4-fluorophenyl group and re-design of the basic sub-
stituent as key strategic aims. By concentrating on cell potency, lipo-
philic ligand efficiency and structural novelty in tandem, compounds
such as 27 in particular were developed to populate a highly desirable
and novel area of chemical space as potent, lower molecular weight,
lipophilically efficient analogues with improved in vitro ADME and se-
lectivity profiles. Studies towards the identification of additional ana-
logues suitable for in vivo studies and further mechanistic considera-
tions are ongoing and will be reported in due course.
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Table 4
Basic substituents at the 7-position.
Compound R1 R2 PfPKG pIC50 Pf HXI pEC50a LLE mLogD MLM % remb
2 7-CH2NMe2 H 8.70 6.44 6.3 2.4 52
24 H 8.44 6.46 6.2 2.2 88
25 7-O(CH2)2NMe2 H 8.13 6.09 5.9 2.2 54
26 7-NH(CH2)2NMe2 H 8.59 nt 6.5 2.1 80
27 7-NH(CH2)2NMe2 Me 8.56 6.28 6.4 2.2 93
29 7-(CH2)2NMe2 H 7.69 6.00 5.8 1.9 65
a nt=not tested.
b % remaining after 30min incubation with mouse liver microsomes.
Table 5
Full in vitro profiles for compounds 2, 13 and 27; a % remaining after 30min
incubation with mouse liver microsomes; b kinetic solubility; c in vitro cyto-
toxicity assay measured in HepG2 human liver-derived cells – concentration at
which half of cells remained viable at 48 h.16
Compound PfPKG
pIC50
Pf HXI
pEC50
LLE mLogD MLM %
rema
Kin sol
(µM)b
HepG2
pEC50c
2 8.70 6.44 6.3 2.4 52 200 < 4.7
13 8.35 6.70 6.8 1.5 53 189 < 5
27 8.56 6.28 6.4 2.2 93 207 < 4.7
Figure 3. Kinase selectivity data for representative imidazopyridines 2, 13 and 27 on screening against a human kinase panel at 1 µM concentration; green < 50%
inhibition; yellow 50–90% inhibition; red > 90% inhibition.29
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